SUKSES (Small Cell Lung Cancer Umbrella Korea Studies): A Phase II Biomarker-Driven Umbrella Study in Relapsed or Refractory SCLC

被引：0
|
作者：
Park, S. [1 ]
Hur, J. Y. [1 ]
Yoon, S. E. [1 ]
Lee, K. [1 ]
Kim, Y. [1 ]
Cho, J. H. [1 ]
Sun, J. [1 ]
Lee, S. [1 ]
Ahn, J. S. [1 ]
Ahn, M. [1 ]
Park, K. [1 ]
机构：
[1] Samsung Med Ctr, Dept Med, Div Hematol Oncol, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
small cell lung cancer;
D O I：
10.1016/j.jtho.2018.08.1381
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.12-05
引用
收藏
页码：S792 / S792
页数：1
相关论文
共 50 条
  • [41] Phase II trial of becatecarin (rebeccamycin analogue) in relapsed sensitive small cell lung cancer (SCLC)
    Dowlati, A.
    Mekhail, T.
    O'Brien, T.
    Rutherford, K.
    Snell, M.
    Ness, A.
    Ma, P.
    Ivy, S. P.
    Halmos, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] TIME for biomarker-driven immunotherapy in non-small-cell lung cancer patients
    Karachaliou, Niki
    Rosell, Rafael
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (02) : 127 - 130
  • [43] An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).
    Lee, Jung-Yun
    Kim, Byoung-Gie
    Kim, Jae-Weon
    Lee, Jung Bok
    Park, Eunhyang
    Kim, Sung Hoon
    Choi, Chel Hun
    Kim, Hee Seung
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] A phase II trial of VNP40101M in patients with relapsed or refractory small cell lung cancer (SCLC) with or without brain metastases
    Mekhail, T.
    Gettinger, S.
    Blumenschein, G., Jr.
    Axelrod, R.
    Haigentz, M.
    Guarino, M. J.
    Cahill, A. L.
    Spigel, D.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
    Francesco Gelsomino
    Marcello Tiseo
    Fausto Barbieri
    Ferdinando Riccardi
    Luigi Cavanna
    Antonio Frassoldati
    Angelo Delmonte
    Lucia Longo
    Claudio Dazzi
    Saverio Cinieri
    Ida Colantonio
    Francesca Sperandi
    Giuseppe Lamberti
    Stefano Brocchi
    Lorenzo Tofani
    Luca Boni
    Andrea Ardizzoni
    British Journal of Cancer, 2021, 125 : 306 - 306
  • [46] A phase I study of weekly topotecan (T) in combination with sorafenib (S) for treatment of relapsed or refractory small cell lung cancer (SCLC).
    Leach, J. W.
    Swenson, K.
    Anderson, E.
    Menge, M. R.
    Tsai, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study
    Blanco, A. Calles
    Mendivil, A. F. Navarro
    de Speville, B. Doger
    Colome, E. Alvarez
    Luken, M. J. De Miguel
    Alvarez, R. M.
    Garcia, V. Moreno
    Ramon, J.
    Valles, M. Arregui
    de la Fuente, E. Corral
    Alcala, D.
    Fernandez, M.
    Morato, J. Rodriguez
    Calvo, E.
    Sanchez, R. Palmero
    Jove, M.
    Felip, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1060 - S1061
  • [48] PHASE II STUDY OF WEEKLY AMRUBICIN IN PATIENTS WITH REFRACTORY OR RELAPSED NON-SMALL CELL LUNG CANCER
    Iwasaku, Masahiro
    Nishiyama, Akihiro
    Watanabe, Naoki
    Kunimasa, Kei
    Tsubouchi, Kazuya
    Oka, Saori
    Yoshioka, Hiroshige
    Kitagawa, Chiyoe
    Saka, Hideo
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S875 - S875
  • [49] A Phase II study of dasatinib in patients with chemo-sensitive relapsed small cell lung cancer (SCLC): CALGB 30602
    Miller, Antonius A.
    Pang, Herbert
    Hodgson, Lydia
    Ramnath, Nithya
    Otterson, Gregory A.
    Vokes, Everett E.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S816 - S817
  • [50] Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer
    Schuette, Wolfgang
    Nagel, Sylke
    Juergens, Stefan
    Bork, Ines
    Wollschlaeger, Bettina
    Schaedlich, Steffen
    Blankenburg, Thomas
    CLINICAL LUNG CANCER, 2005, 7 (02) : 133 - 137
12345